Home>>Signaling Pathways>> Others>>Dexrazoxane hydrochloride

Dexrazoxane hydrochloride

Catalog No.GC50047

Topoisomerase II inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

Dexrazoxane hydrochloride Chemical Structure

Cas No.: 1263283-43-7

Size Price Stock Qty
10 mg
$50.00
In stock
50 mg
$98.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Topoisomerase II inhibitor and intracellular ion chelator. Bridges and stabilizes an interface between two ATPase promoters to inhibit topoisomerase II activity. Cardioprotective when co-administered with doxorubicin; decreases formation of reactive oxygen species (ROS) and activates the PI3K/Akt survival pathway.

Lebrecht et al (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br.J.Pharmacol 151 771 PMID:17519947 |Spallarossa et al (2010) Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexraz. J.Pharmacol.Exp.Ther. 332 87 PMID:19841470 |Classen et al (2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc.Natl.Acad.Sci. 100 10629

Reviews

Review for Dexrazoxane hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dexrazoxane hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.